• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Dicerna Pharmaceuticals, Inc.

    12/28/21 11:11:58 AM ET
    $DRNA
    Major Pharmaceuticals
    Health Care
    Get the next $DRNA alert in real time by email
    POS AM 1 d277734dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on December 28, 2021

    Registration No. 333-224989

    Registration No. 333-223778

    Registration No. 333-214082

    Registration No. 333-202687

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-224989

    POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-223778

    POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-214082

    POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-202687

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Dicerna Pharmaceuticals, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

    Delaware

    (State or Other Jurisdiction of Incorporation)

    20-5993609

    (I.R.S. Employer Identification Number)

    75 Hayden Ave

    Lexington, Massachusetts

    (781) 994-0300

    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

     

     

    Bob D. Brown

    President

    Dicerna Pharmaceuticals, Inc.

    75 Hayden Avenue

    Lexington, Massachusetts 02421

    (617) 621-8097

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

     

     

    Copies to:

    William H. Aaronson

    Davis Polk & Wardwell LLP

    450 Lexington Avenue

    New York, NY 10017

    (212) 450-4000

     

     

    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.  ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment (this “Amendment”) relates to the following Registration Statements on Form S-3 (collectively, the “Registration Statements”) filed by Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Dicerna”) with the Securities and Exchange Commission (the “SEC”):

     

      •  

    Registration Statement on Form S-3 (No. 333-224989), filed with the SEC on May 16, 2018;

     

      •  

    Registration Statement on Form S-3 (No. 333-223778), filed with the SEC on March 19, 2018, as amended by Amendment No. 1 on May 4, 2018;

     

      •  

    Registration Statement on Form S-3 (No. 333-214082), filed with the SEC on October 13, 2016, as amended by Amendment No. 1 on October 27, 2016;and

     

      •  

    Registration Statement on Form S-3 (No. 333-202687), filed with the SEC on March 12, 2015.

    On November 17, 2021, Dicerna entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Novo Nordisk A/S, a Danish aktieselskab (“Novo”), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (“Purchaser”). Pursuant to the Merger Agreement, on December 28, 2021, Purchaser merged with and into Dicerna with Dicerna surviving the merger as a wholly-owned subsidiary of Novo.

    As a result of the consummation of the transactions contemplated by the Merger Agreement, Dicerna has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with the undertakings made by Dicerna in the Registration Statements to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, Dicerna hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lexington, Commonwealth of Massachusetts, on December 28, 2021. No other person is required to sign this Post-Effective Amendment to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

     

    DICERNA PHARMACEUTICALS, INC.
    By:  

    /s/ Bob D. Brown

    Name: Bob D. Brown
    Title: President
    Get the next $DRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRNA

    DatePrice TargetRatingAnalyst
    12/9/2021$28.00 → $38.25Buy → Neutral
    Chardan Capital
    11/19/2021$30.00 → $38.25Outperform → Sector Perform
    RBC Capital
    11/18/2021$32.00 → $38.25Buy → Neutral
    HC Wainwright & Co.
    8/11/2021$36.00 → $25.00Buy → Neutral
    Goldman Sachs
    8/10/2021$34.00 → $28.00Buy
    Chardan Capital
    8/10/2021$38.00 → $32.00Buy
    HC Wainwright & Co.
    8/9/2021$32.00Buy → Neutral
    Citigroup
    8/6/2021$35.00 → $30.00Outperform
    RBC Capital
    More analyst ratings

    $DRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dicerna Pharmaceuticals downgraded by Chardan Capital with a new price target

      Chardan Capital downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $28.00 previously

      12/9/21 4:59:39 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Pharmaceuticals downgraded by RBC Capital with a new price target

      RBC Capital downgraded Dicerna Pharmaceuticals from Outperform to Sector Perform and set a new price target of $38.25 from $30.00 previously

      11/19/21 5:44:25 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Pharmaceuticals downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $32.00 previously

      11/18/21 11:53:19 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Dicerna Pharmaceuticals, Inc.

      SC 13G - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      12/3/21 6:09:54 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      2/12/21 3:36:29 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      2/12/21 10:01:42 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

      Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,

      12/28/21 9:04:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

      Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Novo Nordisk's cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021. As previously announced on November 18, 2021, Novo Nordisk commenced a cash tender offer to purchase all outstanding shares of Dicerna common stock for $38.25 per share in cash, without interest and subject to any withholding of taxes. The expiration of the HSR waiting period satisfies one of the conditions necessary for the consummation of the tender offer. Other conditions remain to be satisfied, inclu

      12/25/21 8:00:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    Financials

    Live finance-specific insights

    See more
    • Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

      Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,

      12/28/21 9:04:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

      – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) – – Company Plans to Unveil First GalXC-Plus™ Extrahepatic Target in Early 2022 – – Cash Runway Extends Into 2025 – – Company to Host Conference Call Today at 8:30 a.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "We had a

      11/9/21 7:30:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

      Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4

      11/2/21 4:05:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Dicerna Announces New Executive Leadership Appointments

      – Rob Ciappenelli Appointed Chief Strategy Officer and Marc Abrams, Ph.D., Promoted to Senior Vice President of Discovery Research – – Kristen Sheppard, Esq., Joins Company as Senior Vice President of Investor Relations and Corporate Communications – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Rob Ciappenelli as Chief Strategy Officer, the promotion of Marc Abrams, Ph.D., to Senior Vice President, Discovery Research and the addition of Kristen Sheppard, Esq., to Dicerna's executive leadership team as Senior Vice President, Investor Rela

      9/22/21 7:30:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 23,350 shares of common stock and 5,675 restricted stock units (“RSUs”) to be distributed among three new employees with a grant date of Jan. 4, 2021 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $22.07

      1/4/21 5:30:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    SEC Filings

    See more
    • SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.

      15-12B - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/10/22 4:59:18 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

      EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/3/22 12:15:12 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

      EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/3/22 12:15:18 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Koppel Adam closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:43:55 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Zeng Ling closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:22:27 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Weissman James B closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:22:10 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care